Learn why this royalty company believes it is the best way to play commodities and inflation. on 06/22/2021. Learn More

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Galera Posts Positive Data from Phase 1/2 Pancreatic Cancer Trial

  ()
Galera Therapeutics shares traded 25% higher after the company reported new data from its Phase 1/2 pilot study of dismutase mimetic GC4419 that when used in combination with radiation therapy was shown to nearly double median overall survival time in patients with locally advanced pancreatic cancer. read more >

ADMA Biologics Granted FDA Approval to Boost IVIG Production by 50%

  ()
ADMA Biologics shares traded 9% higher after the company received FDA approval for increased intravenous immune globulin production scale, allowing the firm to increase manufacturing capacity from 400,000 to 600,000 liters and achieve peak revenues of greater than $300 million. read more >

Biopharma Study Shows Safety of Stem Cell Therapy in Severe COVID-19 Patients

Research Report
  ()
The clinical trial, in which Sorrento Therapeutics established safety, and the company's next steps for this potential treatment are summarized in a Dawson James Securities report. read more >

Aldeyra's Drug Meets All Key Endpoints in Phase 3 Allergic Conjunctivitis Trial

  ()
Aldeyra Therapeutics shares traded 33% higher after the firm reported that reproxalap significantly met all primary and secondary endpoints in its Phase 3 allergic conjunctivitis study. read more >

Ocugen Reports $100 Million Direct Share Offering at Market Premium from Institutional Investors

  ()
Ocugen Inc. shares traded up as much as 47% before closing just 3.66% higher for the day after the company announced a $100 million registered direct offering of common stock priced at a $10 per share, which represents a premium to the market price. read more >

Is the Trend Turning for This Psychedelic Stock?

Contributed Opinion
  ()
Technical analyst Clive Maund charts Delic Inc. and explains why he considers the stock attractive at this point. read more >

Ardelyx to Receive $5M Milestone Payment as Japan Partner Initiates Phase 3

  ()
Ardelyx Inc. shares traded 11% higher after Kyowa Kirin Co. Ltd., its collaborative partner in Japan, initiated four Phase 3 clinical trials of tenapanor for treatment of hyperphosphatemia. read more >

Biotech Company Acquires Therapeutics Firm, Gains 'Gem' in the Portfolio

Research Report
  ()
Dawson James Securities advised it is maintaining its "Buy" rating after Sorrento Therapeutics announced the acquisition of ACEA Therapeutics for $38 million in stock. read more >

Novocure Shares Climb 50% on Acceleration of Phase 3 Lung Cancer Trial

  ()
Novocure Ltd. shares reached a new 52-week high after the company reported an update from its Phase 3 Pivotal LUNAR trial of tumor treating electrical fields in non-small cell lung cancer. read more >

Affimed NV Shares Rise 20% on Initial Data from Phase 1 R/R CD30-Positive Lymphoma Trial

  ()
Affimed NV shares reached a new 52-week high price after the company presented initial data from a Phase 1 trial of its AFM13 that shows potential to help NK cells target and destroy cancer cells. read more >

Gene Therapy Restoring Light Sensitivity 'Showed Impressive Dose-Response Improvements'

Research Report
  ()
Roth Capital Partners advised that Applied Genetic Technologies co-development of BS01 with Bionic Sight "validates its gene therapy capabilities." read more >

Biopharma's Phase 2b/3 Alzheimer's Disease Trial Approved to Continue

Research Report
  ()
Anavex Life Sciences' study, its drug's mechanism of action and the company's upcoming catalysts are covered in a Dawson James Securities report. read more >

Biohaven Expects Net Revenue of $43.8 Million in Q1 for Its Migraine Medicine

  ()
Biohaven Pharmaceutical shares traded 10% higher after the company reported that in Q1/21 net product revenue for its migraine drug NURTEC ODT is estimated to be approximately $43.8 million. read more >

United Therapeutics Shares Rise 15% as FDA Clears Pathway to Launch Tyvaso to Treat PH-ILD

  ()
United Therapeutics shares reached a new 52-week high after the firm reported that the U.S. FDA granted approval to commercially launch its Tyvaso® Inhalation Solution to treat patients with pulmonary hypertension associated with interstitial lung disease. read more >
News Update

Pharmaceutical Development Company Added to First Psychedelic Stock Index ETF

News Update
  ()
Being included in the Horizons Psychedelic Stock Index Exchange Traded Fund will afford Algernon Pharmaceuticals greater investor exposure. read more >

Data from Humanigen's Phase 3 COVID-19 Trial Show 54% Increase in Survival Rates

  ()
Shares of Humanigen Inc. traded 67% higher after the company reported positive topline results from its Phase 3 lenzilumab™ study indicating significant improvement in survival of hospitalized COVID-19 pneumonia patients without the need for mechanical ventilation. read more >

ProQR Shares Gain 62% on Stellar Results in Phase 1/2 Usher Syndrome Trial

  ()
ProQR Therapeutics shares reached a new 52-week high after the company reported highly positive results from its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations. read more >

Aptose Biosciences Shares Rise 55% on Q4 Financial Results and Promising Clinical Trials

  ()
Aptose Biosciences Inc. shares traded 55% higher after the company posted Q4 and FY/20 financial results and provided an update on the status of its drug candidates in ongoing clinical trials investigating treatments for life threatening hematologic cancers. read more >

Biopharma to Request U.S. Emergency Use Authorization for COVID-19 Vaccine in April

Research Report
  ()
Catalysts expected in 2021-2022 regarding Ocugen's pipeline therapeutics are discussed in a ROTH Capital Partners report. read more >

The Covid-19 Issue Too Many Are Ready to Overlook, and the Investing Opportunity It Creates

Contributed Opinion
  ()
Have we forgotten about good Covid 19 Therapeutics? KSS MD PhD, editor-in-chief of PubBio.co, discusses three gems investors should know about. read more >
News Update

Mental Health Firm Partners with Merck on Treatment-Resistant Depression Trial

News Update
  ()
Novamind Inc. reported it is teaming up with Merck to conduct a new Phase 2a study addressing treatment-resistant depression at a key clinical research site owned by its subsidiary company Cedar Clinical Research. read more >

Clovis Oncology Shares Rise on Positive Data from Phase 3 Ovarian Cancer Trial

  ()
Shares of Clovis Oncology Inc. traded 55% higher after it reported that in the Phase 3 ARIEL4 study Rubraca (rucaparib) significantly improved progression-free survival versus chemotherapy in patients with later-line ovarian cancer associated with a BRCA Mutation. read more >

Biopharma Advances Alcohol-Associated Hepatitis Trial, Receives Analgesia Drug Approval

Research Report
  ()
These corporate events and the Q4/20 financials of DURECT are summarized in an H.C. Wainwright & Co. report. read more >
News Update

Pharma Developer to Release Topline Data from Phase 2b COVID-19 Trial by Month-End

News Update
  ()
Algernon Pharmaceuticals reported expects to release topline results from the Phase 2b portion of its multinational Phase 2b/3 COVID-19 Ifenprodil study sometime during the last week of March 2021. read more >

Oncternal Therapeutics Shares Trade Higher After Firm Reports 39% Growth in FY20 Grant Revenue

  ()
Oncternal Therapeutics shares traded 18% higher after the company reported Q4/20 and FY/20 financial results showing higher revenues from grants and improved operating expense without incurring any reductions in Research and Development activities. read more >
Showing Results: 26 to 50 of 97 Prev Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe